Epirubicin Accord 2 mg/ml injektions-/infusionsvätska

DRUG2 trials

Sponsors

Karolinska University Hospital, Karolinska Institutet

Conditions

Breast cancer female NOSNon-metastatic HER2-positive Breast Cancer

Phase 2

A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE

RecruitingCTIS2022-501504-95-00

Karolinska University HospitalNon-metastatic HER2-positive Breast Cancer

Start: 2023-06-23Target: 402Updated: 2025-08-18

Phase 4

TailorDose®-II: Therapeutic dose monitoring of commonly used cytostatic drugs/regimes indicated for breast cancer

Not yet recruitingCTIS2024-514818-12-00

Karolinska InstitutetBreast cancer female NOS

Target: 200Updated: 2025-11-13

Related Papers

Method-Comparison Validation of a Novel Capillary Blood Collection Kit, True Dose® TD-EPI, for Therapeutic Drug Monitoring of Epirubicin

Pharmaceuticals2026-01-28

Development and evaluation of a novel capillary blood collection method for decentralized therapeutic drug monitoring using the True Dose kit.

2025-09-29

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE

BMJ Open2025-08-011 citations

Capillary Blood Self-Sampling for Therapeutic Drug Monitoring: A Mixed-Methods Usability Study of the True Dose<sup>®</sup> Kit.

2025-07-09

Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.

2025-03-073 citations